| Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles A Biscans, J Caiazzi, N McHugh, V Hariharan, M Muhuri, A Khvorova Molecular Therapy 29 (4), 1382-1394, 2021 | 83 | 2021 |
| Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington’s disease D O'Reilly, J Belgrad, C Ferguson, A Summers, E Sapp, C McHugh, ... Molecular Therapy 31 (6), 1661-1674, 2023 | 58 | 2023 |
| Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1 SM Davis, VN Hariharan, A Lo, AA Turanov, D Echeverria, J Sousa, ... Molecular Therapy Nucleic Acids 29, 135-149, 2022 | 54 | 2022 |
| Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin Q Tang, HH Fakih, M Zain UI Abideen, SR Hildebrand, K Afshari, ... Nature Communications 14 (1), 7099, 2023 | 51 | 2023 |
| Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection VN Hariharan, M Shin, CW Chang, D O’Reilly, A Biscans, K Yamada, ... Proceedings of the National Academy of Sciences 120 (11), e2219523120, 2023 | 50 | 2023 |
| Enhancing siRNA efficacy in vivo with extended nucleic acid backbones K Yamada, VN Hariharan, J Caiazzi, R Miller, CM Ferguson, E Sapp, ... Nature Biotechnology 43 (6), 904-913, 2025 | 34 | 2025 |
| Cyclic di‐GMP sensing histidine kinase PdtaS controls mycobacterial adaptation to carbon sources VN Hariharan, R Yadav, C Thakur, A Singh, R Gopinathan, DP Singh, ... The FASEB Journal 35 (4), e21475, 2021 | 27* | 2021 |
| Dendritic amphiphilic siRNA: selective albumin binding, in vivo efficacy, and low toxicity HH Fakih, Q Tang, A Summers, M Shin, JE Buchwald, R Gagnon, ... Molecular Therapy Nucleic Acids 34, 2023 | 18 | 2023 |
| Extended nucleic acid (exNA): a novel, biologically compatible backbone that significantly enhances oligonucleotide efficacy in vivo K Yamada, VN Hariharan, J Caiazzi, R Miller, C Furguson, E Sapp, ... bioRxiv, 2023 | 15 | 2023 |
| Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for … S Engelbeen, D O'Reilly, D Van De Vijver, I Verhaart, M Van Putten, ... nucleic acid therapeutics 33 (6), 348-360, 2023 | 11 | 2023 |
| Finding hidden females in a crowd: Mate recognition in fig wasps A Krishnan, KA Joshi, A Abraham, S Ayyub, M Lahiry, R Mukherjee, ... Acta Oecologica 57, 80-87, 2014 | 11 | 2014 |
| Systematic analysis of siRNA and mRNA features impacting fully chemically modified siRNA efficacy SM Davis, S Hildebrand, HJ MacMillan, KR Monopoli, J Buchwald, ... Nucleic Acids Research 53 (12), gkaf479, 2025 | 9 | 2025 |
| Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders A Khvorova, VN Hariharan, S Davis, A BISCANS, A Karumanchi US Patent 11,702,659, 2023 | 9 | 2023 |
| Oligonucleotides for SARS-CoV-2 modulation A Khvorova, J Watts, Z Kennedy, A BISCANS, BM da Cruz Godinho, ... US Patent 12,077,758, 2024 | 7 | 2024 |
| Oligonucleotides for mecp2 modulation A Khvorova, VN Hariharan US Patent App. 18/094,695, 2023 | 7 | 2023 |
| Phosphatidylcholine head group chemistry alters the extrahepatic accumulation of lipid-conjugated siRNA VN Hariharan, T Nakamura, M Shin, Q Tang, V Sontakke, J Caiazzi, ... Molecular Therapy Nucleic Acids 35 (2), 2024 | 6 | 2024 |
| A combinatorial approach for achieving CNS-selective RNAi CM Ferguson, BMDC Godinho, D Echeverria, M Hassler, L Vangjeli, ... Nucleic Acids Research 52 (9), 5273-5284, 2024 | 6 | 2024 |
| Two-Component Signalling Systems of M. tuberculosis: Regulators of Pathogenicity and More R Agrawal, VH Narayan, DK Saini Dynamic Models of Infectious Diseases: Volume 2: Non Vector-Borne Diseases …, 2013 | 6 | 2013 |
| Single-dose administration of therapeutic divalent siRNA targeting MECP2 prevents lethality for one year in an MECP2 duplication mouse model VN Hariharan, A Summers, AE Clipperton-Allen, J Caiazzi, ... bioRxiv, 2025 | 4 | 2025 |
| Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders A Khvorova, VN Hariharan, S Davis, A BISCANS, A Karumanchi US Patent App. 18/321,971, 2024 | 3 | 2024 |
